Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | EVP, R&D & Chief Scientific Of | February 15, 2019 | February 19, 2019 |
| Elicio Therapeutics, Inc.ELTX · Entity 299 | See Remarks | July 16, 2026 | July 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atara Biotherapeutics, Inc.
Report date February 15, 2019 · Filed February 19, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 271,943 |
Reported balance
After 2019-02-15 transaction · row 1
1 source rowRow 1 · 2019-02-15 · Sale · Disposed 775 · Balance 271,943 F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F2: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.33 to $39.695. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 17,312 |
Reported balance
Holding disclosure · report date 2019-02-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 17,312 F3: The shares are held by the Chris Haqq 2014 GRAT, of which the Reporting Person is trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,688 |
Reported balance
Holding disclosure · report date 2019-02-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,688 F4: The shares are held by The Havenside Trust, of which the Reporting Person is trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018.
F2: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.33 to $39.695. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: The shares are held by the Chris Haqq 2014 GRAT, of which the Reporting Person is trustee.
F4: The shares are held by The Havenside Trust, of which the Reporting Person is trustee.
Elicio Therapeutics, Inc.
Report date July 16, 2026 · Filed July 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.20 · Expires 2036-07-16 | Direct | 64,643 |
Reported balance
After 2026-07-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-16 · Grant · Acquired 64,643 · Balance 64,643 F1: The stock option vests and becomes exercisable as to 50% of the options on July 16, 2027, the first anniversary of the grant date, and as to the remaining 50% of the options on July 16, 2028, the second anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable as to 50% of the options on July 16, 2027, the first anniversary of the grant date, and as to the remaining 50% of the options on July 16, 2028, the second anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Surrozen, Inc./DE
Report date August 11, 2021 · Filed August 13, 2021
Section 16 reporting ended · disclosed 2021-08-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,000 |
Reported balance
After 2021-08-11 transaction · row 1
1 source rowRow 1 · 2021-08-11 · Grant · Acquired 30,000 · Balance 30,000 F1: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.", F2: (Continued from Footnote 1) (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination". |
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-08-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-08-11 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.", F2: (Continued from Footnote 1) (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination". |
Filing footnotes · ownership attribution and instrument terms
F1: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.",
F2: (Continued from Footnote 1) (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination".
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 16, 2026 Filed Jul 17, 2026 20:14 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 64,643 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001612095-26-000002 · wk-form4_1784319276.xml · derivative · entry 1 Haqq Christopher · CIK 0001612095 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,643 Underlying: Common Stock · 64,643 shares Expires 2036-07-16 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 50% of the options on July 16, 2027, the first anniversary of the grant date, and as to the remaining 50% of the options on July 16, 2028, the second anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:33 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 50,900 | $0.00 Strike: $8.10 | $0.00 |
DisclosureSEC source: 0001601485-26-000002 · wk-form4_1770154430.xml · derivative · entry 2 Haqq Christopher · CIK 0001612095 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,900 Underlying: Common Stock · 50,900 shares Expires 2036-02-02 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the options on February 2, 2027, the first anniversary of the grant date, with the remaining options vesting in monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:33 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantCommon Stock | 25,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001601485-26-000002 · wk-form4_1770154430.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,381 F1 · shares: Represents restricted stock units ("RSUs") that will vest as to 25% of the RSUs on February 2, 2027, the first anniversary of the grant date, with the remaining RSUs vesting in annual installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Each RSU represents the right to receive one share of common stock, par value $0.01 per share, of the Issuer. F1 · price: Represents restricted stock units ("RSUs") that will vest as to 25% of the RSUs on February 2, 2027, the first anniversary of the grant date, with the remaining RSUs vesting in annual installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Each RSU represents the right to receive one share of common stock, par value $0.01 per share, of the Issuer. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 21:10 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 44,000 | $0.00 Strike: $8.92 | $0.00 |
DisclosureSEC source: 0001601485-25-000014 · wk-form4_1738703424.xml · derivative · entry 1 Haqq Christopher · CIK 0001612095 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2035-02-03 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the options on the first anniversary of the grant date (February 3, 2026), with the remaining options vesting in equal monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 20:12 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 28,200 | $0.00 Strike: $5.03 | $0.00 |
DisclosureSEC source: 0001601485-24-000049 · wk-form4_1727899926.xml · derivative · entry 1 Haqq Christopher · CIK 0001612095 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,200 Underlying: Common Stock · 28,200 shares Expires 2024-09-30 F1 · derivative.exercise_date: Fifty percent (50%) of the stock options vest on September 30, 2025, the one-year anniversary of the grant date, with the remaining fifty percent (50%) of the stock options to vest on September 30, 2026, the two-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 11:01 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (right to buy) · Derivative | 28,200 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001140361-24-005497 · form4.xml · derivative · entry 1 Haqq Christopher · CIK 0001612095 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,200 Underlying: Common Stock · 28,200 shares Expires 2034-02-01 F1 · derivative.exercise_date: Twenty five percent (25%) of the stock options vest on February 1, 2025, the one-year anniversary of the grant date, with the remaining options vesting in monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| August 11, 2021 Filed Aug 13, 2021 23:38 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | Disposition to issuerClass B Ordinary Shares · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-033040 · doc4.xml · derivative · entry 2 Haqq Christopher · CIK 0001612095 · Former Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 30,000 shares Expires not disclosed F1 · security: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.", F2 · security: (Continued from Footnote 1) (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination". F1 · derivative.exercise_price: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.", F2 · derivative.exercise_price: (Continued from Footnote 1) (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination". F1 · derivative.exercise_date: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.", F2 · derivative.exercise_date: (Continued from Footnote 1) (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination". F1 · derivative.expiration_date: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.", F2 · derivative.expiration_date: (Continued from Footnote 1) (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination". Read SEC document |
| August 11, 2021 Filed Aug 13, 2021 23:38 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | GrantCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-033040 · doc4.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · Former Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · price: On April 15, 2021, Consonance-HFW Acquisition Corp. (the "Issuer") entered into a Business Combination Agreement (the "Business Combination Agreement"), by and among the Issuer, Perseverance Merger Sub Inc. ("Merger Sub"), and Surrozen, Inc. ("Surrozen"). The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021. Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the "Domestication") and, in connection with the Domestication, (A) the Issuer's name changed to "Surrozen, Inc.", F2 · price: (Continued from Footnote 1) (B) each outstanding Class A Ordinary Share of the Issuer ("Class A Share") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the "Common Stock") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), pursuant to Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the "Merger"). The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the "Business Combination". Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 22:08 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 775 | $39.59 | $30,682.25 |
DisclosureSEC source: 0001209191-19-011187 · doc4.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,943 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.33 to $39.695. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 11, 2019 Filed Feb 12, 2019 00:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 13,975 | $38.55 | $538,736.25 |
DisclosureSEC source: 0001209191-19-009116 · doc4.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,718 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.27 to $38.55. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:28 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $38.47 | $0.00 |
DisclosureSEC source: 0001209191-19-008526 · doc4.xml · derivative · entry 7 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-02-05 F8 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month following February 6, 2019, subject to the reporting person's continuous service. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:28 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008526 · doc4.xml · nonDerivative · entry 4 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,693 F5 · shares: These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant date, subject to the reporting person's continuous service. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:28 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Tax withholdingCommon Stock | 1,512 | $38.47 | $58,166.64 |
DisclosureSEC source: 0001209191-19-008526 · doc4.xml · nonDerivative · entry 3 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,693 F4 · kind: Shares withheld to cover tax obligation from settlement of vested restricted stock units. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:28 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 9,698 | $38.78 | $376,088.44 |
DisclosureSEC source: 0001209191-19-008526 · doc4.xml · nonDerivative · entry 2 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,205 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.67 to $38.89. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:28 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,677 | $38.04 | $101,833.08 |
DisclosureSEC source: 0001209191-19-008526 · doc4.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,903 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $37.61 to $38.54. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 15, 2018 Filed Nov 15, 2018 21:53 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 775 | $33.81 | $26,202.75 |
DisclosureSEC source: 0001209191-18-058763 · doc4.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,580 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $33.65 to $34.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 26, 2018 Filed Sep 27, 2018 20:56 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 13,500 | $43.08 | $581,580.00 |
DisclosureSEC source: 0001209191-18-052465 · doc4.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,355 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $42.70 to $43.525. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 25, 2018 Filed Sep 25, 2018 21:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,500 | $41.23 | $144,305.00 |
DisclosureSEC source: 0001209191-18-052162 · doc4.xml · nonDerivative · entry 4 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,855 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $41.10 to $41.475. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 25, 2018 Filed Sep 25, 2018 21:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 10,000 | $40.26 | $402,600.00 |
DisclosureSEC source: 0001209191-18-052162 · doc4.xml · nonDerivative · entry 3 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,355 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.975 to $40.95. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 24, 2018 Filed Sep 25, 2018 21:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,931 | $40.53 | $159,323.43 |
DisclosureSEC source: 0001209191-18-052162 · doc4.xml · nonDerivative · entry 2 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,355 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.20 to $40.70. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 24, 2018 Filed Sep 25, 2018 21:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 14,069 | $39.74 | $559,102.06 |
DisclosureSEC source: 0001209191-18-052162 · doc4.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,286 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.15 to $40.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 21:12 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 775 | $37.54 | $29,093.50 |
DisclosureSEC source: 0001209191-18-047107 · doc4.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,355 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $37.20 to $37.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 15, 2018 Filed May 17, 2018 00:37 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001209191-18-030722 · doc4.xml · derivative · entry 7 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2021-10-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F7 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month following October 15, 2014. Read SEC document |
| May 15, 2018 Filed May 17, 2018 00:37 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 9,252 | $46.02 | $425,777.04 |
DisclosureSEC source: 0001209191-18-030722 · doc4.xml · nonDerivative · entry 4 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,130 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $45.85 to $46.30. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 15, 2018 Filed May 17, 2018 00:37 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 9,638 | $45.21 | $435,733.98 |
DisclosureSEC source: 0001209191-18-030722 · doc4.xml · nonDerivative · entry 3 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,382 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $44.80 to $45.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 15, 2018 Filed May 17, 2018 00:37 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 6,885 | $44.44 | $305,969.40 |
DisclosureSEC source: 0001209191-18-030722 · doc4.xml · nonDerivative · entry 2 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,020 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $43.75 to $44.75. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 15, 2018 Filed May 17, 2018 00:37 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 25,000 | $11.00 | $275,000.00 |
DisclosureSEC source: 0001209191-18-030722 · doc4.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357,905 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. Read SEC document |
| March 26, 2018 Filed Mar 27, 2018 20:16 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,100 | $40.29 | $44,319.00 |
DisclosureSEC source: 0001209191-18-021728 · doc4.xml · nonDerivative · entry 2 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,905 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.20 to $40.50. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 26, 2018 Filed Mar 27, 2018 20:16 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 17,227 | $39.76 | $684,945.52 |
DisclosureSEC source: 0001209191-18-021728 · doc4.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,005 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.15 to $40.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 15, 2018 Filed Feb 21, 2018 01:24 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 553 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011670 · doc4.xml · derivative · entry 4 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 553 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F5 · derivative.exercise_date: Fully vested. F6 · derivative.expiration_date: The earlier of (i) January 10, 2021 or (ii) the recipient's termination date. Read SEC document |
| February 15, 2018 Filed Feb 21, 2018 01:24 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 553 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011670 · doc4.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 01:55 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Tax withholdingCommon Stock | 4,925 | $41.70 | $205,372.50 |
DisclosureSEC source: 0001209191-18-009408 · doc4.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,679 F1 · kind: Shares withheld to cover tax obligation from settlement of vested restricted stock units. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 22:46 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $35.80 | $0.00 |
DisclosureSEC source: 0001209191-18-008513 · doc4.xml · derivative · entry 5 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2025-02-06 F5 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month following February 6, 2018. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 22:46 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Tax withholdingCommon Stock | 4,426 | $35.80 | $158,450.80 |
DisclosureSEC source: 0001209191-18-008513 · doc4.xml · nonDerivative · entry 2 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,604 F2 · kind: Shares withheld to cover tax obligation from settlement of vested restricted stock units. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 22:46 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008513 · doc4.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,030 F1 · shares: These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant date, subject to the reporting person's continuous service. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 23:27 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 829 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-061608 · doc4.xml · derivative · entry 5 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 553 Underlying: Common Stock · 829 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F7 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 1/48th of the total number of shares shall vest monthly from January 10, 2014, subject to the holder's continuous service through each such date. F8 · derivative.expiration_date: The earlier of (i) January 10, 2021 or (ii) the recipient's termination date. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 23:27 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,604 | $13.36 | $21,429.44 |
DisclosureSEC source: 0001209191-17-061608 · doc4.xml · nonDerivative · entry 2 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,530 F2 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 27, 2016. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $13.25 to $13.55. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 23:27 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 829 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-061608 · doc4.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| October 16, 2017 Filed Oct 17, 2017 20:46 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 6,000 | $14.35 | $86,100.00 |
DisclosureSEC source: 0001209191-17-057159 · doc4.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,305 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 27, 2016. Read SEC document |
| September 15, 2017 Filed Sep 18, 2017 21:46 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 6,000 | $15.30 | $91,800.00 |
DisclosureSEC source: 0001209191-17-053206 · doc4.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,305 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 27, 2016. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 21:35 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 829 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-049448 · doc4.xml · derivative · entry 5 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,382 Underlying: Common Stock · 829 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F6 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 1/48th of the total number of shares shall vest monthly from January 10, 2014, subject to the holder's continuous service through each such date. F7 · derivative.expiration_date: The earlier of (i) January 10, 2021 or (ii) the recipient's termination date. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 21:35 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 7,604 | $14.75 | $112,159.00 |
DisclosureSEC source: 0001209191-17-049448 · doc4.xml · nonDerivative · entry 2 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,305 F2 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 27, 2016. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 21:35 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 829 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-049448 · doc4.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| July 17, 2017 Filed Jul 18, 2017 20:24 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 6,000 | $14.92 | $89,520.00 |
DisclosureSEC source: 0001209191-17-045509 · doc4.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,080 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 27, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.9161 to $14.95. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 20:47 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 6,000 | $12.65 | $75,900.00 |
DisclosureSEC source: 0001209191-17-040561 · doc4.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,080 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 27, 2016. Read SEC document |
| May 15, 2017 Filed May 17, 2017 20:58 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 829 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033195 · doc4.xml · derivative · entry 5 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,211 Underlying: Common Stock · 829 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F7 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 1/48th of the total number of shares shall vest monthly from January 10, 2014, subject to the holder's continuous service through each such date. F8 · derivative.expiration_date: The earlier of (i) January 10, 2021 or (ii) the recipient's termination date. Read SEC document |
| May 15, 2017 Filed May 17, 2017 20:58 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 7,604 | $14.99 | $113,983.96 |
DisclosureSEC source: 0001209191-17-033195 · doc4.xml · nonDerivative · entry 2 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,080 F2 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted December 7, 2015. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.65 to $15.20. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 15, 2017 Filed May 17, 2017 20:58 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 829 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033195 · doc4.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 20:29 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 6,000 | $17.28 | $103,680.00 |
DisclosureSEC source: 0001209191-17-027470 · doc4.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,855 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 27, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $17.00 to $17.55. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 21:07 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 6,000 | $19.60 | $117,600.00 |
DisclosureSEC source: 0001209191-17-021452 · doc4.xml · nonDerivative · entry 1 Haqq Christopher · CIK 0001612095 · EVP, R&D & Chief Scientific Of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,855 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted December 7, 2015. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.